Uncategorized

Economics of Clinic Dispensing II

This post continues my discussion of the economics of physician dispensing. If you take a general practice physician and look at his/her prescribing patterns, you will notice similar trends among practices.  As an example, I will use a mature family practice with a single physician.  We tracked his prescriptions and medication dispensing over a five day period.  He averaged 19 prescriptions a day.  About 53% of his scripts are items that can be dispensed from his office.  So, every day he is dispensing about 10 items to his patients.

In this case, the physician's average price per prescription is $15.  The average cost to the physician for each medication dispensed is $3.25.  The clinic is generating $11.75 per script of gross profit; $117.50 per day.  Let's assume that the practice is operating 45 weeks of the year, this makes the physician's annual profit $26,438.  In this case, the physician did not need to add any additional head count and most of these items are less expensive to the patient than going to a pharmacy and using their health insurance.

Conclusion: medication dispensing is not a "get rich quick" program but a viable supplement to a responsible practice.  With virtually no additional overhead cost, medication dispensing can add enough cash to help offset costs in other areas and increase the physician's net revenue from the practice.  In addition, pharmaceutical dispensing helps save the patient money and adds value through convenience.  Sounds like a win-win to me.

Schedule a free claims analysis now.

Let’s Talk now

Healthcare Storm 2025: What Will It Be?

Phillip Berry | Jan 1st, 2025
When it comes to American healthcare, we’ve become really good at highlighting its failings. Watching the flurry of lamentations, frustrations, denigrations, and prognostications, over the last few weeks, would lead any rational person to believe that nothing is working in our healthcare system. And, not only is it “not working,” many people conclude that it … more »

continue reading

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading

Letter From a Pharmacist – On Pharmacy Closures

Phillip Berry | Oct 25th, 2024
Pharmacists have a time-honored role as an integral contributor to the delivery of health care. From the earliest apothecaries to the retail stores of today, community pharmacists have provided guidance about health, wellness and medication therapy. Their expertise ranges from preventive care to the most advanced medications used in the treatment of complex disease.  Despite … more »

continue reading